Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
November 6, 2018 4:15 PM ESTTotal revenue of $103.0 million, a 28% increase over 2017Net product sales of $100.2 million, a 28% increase over 2017Operating earnings of $37.5 million, a 68% increase over 2017Diluted earnings per share (GAAP) of $0.52, a 79% increase over 2017Data from first three Phase III SPN-812 trials expected in December 2018Acquisition of Biscayne Neurotherapeutics, Inc. closed in October 2018Ranked #1 fastest growing pharmaceutical company worldwide per Fortune 100 fastest growing companies
ROCKVILLE, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for... More
